Olema Pharmaceuticals is a clinical-stage biopharmaceutical company that develops therapies for women's cancers. Its lead product candidate, OP-1250, is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was founded in 2006 and is headquartered in San Francisco, California.